Effect of Alendronate on Serum Total Alkaline Phosphatase and Bone Specific Alkaline Phosphatase in Elderly Female Patients with Postmenopausal Osteoporosis
- VernacularTitle:阿仑膦酸钠对绝经后骨质疏松症老年女性血清总碱性磷酸酶、骨特异性碱性磷酸酶的影响
- Author:
Xinyi WANG
;
Bensheng ZHANG
;
Xiaorong LIU
;
Zhongyin ZHANG
- Keywords:
Postmenopausal;
Osteoporosis;
Alendronate;
Serum total alkaline phosphatase;
Bone specific alkaline phosphatase
- From:
China Pharmacist
2017;20(7):1260-1261,1298
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect of alendronate on serum total alkaline phosphatase (AKP) and bone specific alkaline phosphatase (BAP) in the elderly female patients with postmenopausal osteoporosis and explore their correlations.Methods: A retrospective study was performed.Totally 286 elderly female patients with postmenopausal osteoporosis were divided into two groups(according to AKP levels before the treatment of alendronate): the normal AKP group (n=245) and the elevated AKP group (n=41).Raised AKP of all the patients in the elevated AKP group was not associated with hepatobiliary problems.The changes of AKP and BAP levels were analyzed after the treatment of alendronate.The correlations between BAP and AKP levels before and after the treatment of alendronate were analyzed, as well as between the changes in AKP (ΔAKP) and BAP (ΔBAP) levels.Results: AKP and BAP tended to be higher in elderly patients.BAP levels in the normal AKP group were higher than those in the elevated AKP group (P＜0.05).BAP was signicantly correlated with AKP both before and after the treatment (P＜0.05), as well as the correlation between ΔAKP and ΔBAP (P＜0.05).Conclusion: AKP and BAP both tend to increase with age.In elderly female patients with postmenopausal osteoporosis and elevated AKP associated with non-hepatobiliary problems, alendronate treatment can lower AKP levels, and the decrease is strongly correlated with the decrease in BAP.
